Recently, idelalisib, an oral PI3K p110δ inhibitor, was investigated in a Phase 3 clinical trial in patients with indolent non-Hodgkin's lymphoma, CLL, and mantle cell lymphoma [26]. Here, PIK3CD is linked to non-Hodgkin lymphoma.